1. Guillain-Barré syndrome
Prof Hugh J Willison, MBBS, Prof Bart C Jacobs, MD, Prof Pieter A van Doorn, MD 
The Lancet 
Volume 388, Issue 10045, Pages (August 2016)
DOI: /S (16)
Copyright © 2016 Elsevier Ltd Terms and Conditions

2. Figure 1 Guillain-Barré syndrome time course
The Lancet  , DOI: ( /S (16) )
Copyright © 2016 Elsevier Ltd Terms and Conditions

3. Figure 2
Major Guillain-Barré syndrome subtypes in which antibody-mediated effector pathways, including complement activation, cause glial or axonal membrane injury with consequent conduction failure
The Lancet  , DOI: ( /S (16) )
Copyright © 2016 Elsevier Ltd Terms and Conditions

4. Figure 3 Treatment approach for Guillain-Barré syndrome
Modified with permission from van den Berg and colleagues.4 Solid lines are treatment flow; dashed lines are issues that need to be considered. ICU=intensive care unit. EGRIS=Erasmus GBS Respiratory Insufficiency Score. IVIg=intravenous immunoglobulin. TRF=treatment related fluctuation.
The Lancet  , DOI: ( /S (16) )
Copyright © 2016 Elsevier Ltd Terms and Conditions